Of note, we demonstrated systematic improvements on muscle mass, insulin sensitivity, lipid parameters, fat mass, and hepatic steatosis after AAV‐NLS‐PGC1α4 delivery in muscle. The gene discussed is INS; the disease is fatty liver disease.